Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xiuzheng Pharmaceutical To Build Pharmaceutical Hub In Fujian

This article was originally published in PharmAsia News

Executive Summary

Xiuzheng Pharmaceutical Group has signed an MOU with Yongchun county government to set up a production, R&D and sales base. This will be built upon Fujian Yongchun Pharmaceutical Factory's infrastructure, which it acquired last August. According to the agreement, Yongchun Pharmaceutical Factory will be Xiuzheng's pharmaceutical parent company in Fujian to control the group's drug production and distribution business in the southeast province. In addition, a logistics center will also be established, with Fujian as the hub to cover south, east and central China. Xiuzheng will inject RMB 300 million into Yongchun county and aims to hit RMB 3 billion annual production after completing the investment. (Click here for more - Chinese Language)

You may also be interested in...

Trump Most-Favored-Nation Pricing Rule Criticized By The AAM

Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”

Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts